Vcanbio Cell & Gene Engineering Corp., Ltd (SHA:600645)
China · Delayed Price · Currency is CNY 23.85
-0.31 (-1.28%)
Sep 26, 2025, 2:45 PM CST
SHA:600645 Revenue
Vcanbio Cell & Gene Engineering Corp., had revenue of 365.58M CNY in the quarter ending June 30, 2025, a decrease of -9.58%. This brings the company's revenue in the last twelve months to 1.50B, down -5.92% year-over-year. In the year 2024, Vcanbio Cell & Gene Engineering Corp., had annual revenue of 1.59B, down -0.27%.
Revenue (ttm)
1.50B
Revenue Growth
-5.92%
P/S Ratio
7.24
Revenue / Employee
744.54K
Employees
2,014
Market Cap
10.85B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.59B | -4.30M | -0.27% |
| Dec 31, 2023 | 1.59B | 34.84M | 2.24% |
| Dec 31, 2022 | 1.55B | 19.56M | 1.27% |
| Dec 31, 2021 | 1.54B | 216.43M | 16.41% |
| Dec 31, 2020 | 1.32B | -67.88M | -4.90% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jiangsu Hengrui Medicine | 30.15B |
| WuXi AppTec | 41.90B |
| Shenzhen Mindray Bio-Medical Electronics | 32.94B |
| Sichuan Biokin Pharmaceutical | 441.19M |
| Zhangzhou Pientzehuang Pharmaceutical., | 10.52B |
| Shanghai United Imaging Healthcare | 10.98B |
| Aier Eye Hospital Group | 21.94B |
| Yunnan Baiyao Group Co.,Ltd | 40.84B |